Trial Profile

Can PET study by using [11C] PK11195 radioligand acting to S1P receptors reduce the microglia-tissue activity in the brain of MS patients?

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 30 Mar 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fingolimod (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use

Most Recent Events

17 Sep 2016 Status changed from recruiting to completed.
17 Sep 2016 Primary endpoint has not been met. (Microglia activity is measured by PET imaging and 11C-PK11195 radiogland)
17 Sep 2016 Results presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com